Medicare Expands Coverage of Molecular Cancer Screening Tests
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
The health plan issued a new policy expanding coverage of molecular genetic tests for personalized cancer diagnosis, prognosis, and treatment.
Here’s an approach to ensure your lab patients have the most positive financial experience possible.
Congress fails to include SALSA in the omnibus federal government spending bill passed at the end of 2022, but delays PAMA price cuts once again.
Automating travel and expense significantly improves performance, but adding mobility takes such improvements to a much higher level.
ACLA and public health experts warn that current reimbursement rates will hamper US efforts to contain monkeypox spread.
Revised final rule essentially disarms the threat of insurers having the advantage in out-of-network price disputes.
While the rule is not yet final, it’s likely that labs will have to pay more in direct CLIA compliance expenses, starting in October.
The way the No Surprises Act is implemented would essentially allow private health plans to set out-of-network rates in billing disputes.